Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 95% Improvement Relative Risk c19hcq.org Chechter et al. HCQ for COVID-19 EARLY TREATMENT Is early treatment with HCQ+AZ beneficial for COVID-19? Prospective study of 72 patients in Brazil Lower hospitalization with HCQ+AZ (p=0.0037) Chechter et al., medRxiv, doi:10.1101/2021.11.05.21265569 Favors HCQ Favors control
Evaluation of patients treated by telemedicine in the COVID-19 pandemic by a private clinic in Sao Paulo, Brazil: A non-randomized clinical trial preliminary study
Chechter et al., medRxiv, doi:10.1101/2021.11.05.21265569 (Preprint)
Chechter et al., Evaluation of patients treated by telemedicine in the COVID-19 pandemic by a private clinic in Sao Paulo,.., medRxiv, doi:10.1101/2021.11.05.21265569 (Preprint)
Nov 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective study of 187 telemedicine patients in Brazil. 74 presenting with moderate symptoms were offered treatment with HCQ+AZ, 12 did not accept HCQ (taking AZ only), forming a control group. There was lower hospitalization and improved recovery with treatment. There appears to be different group sizes in the text and tables without explanation (maybe a typo). RBR-658khm. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of hospitalization, 94.7% lower, RR 0.05, p = 0.004, treatment 0 of 60 (0.0%), control 3 of 12 (25.0%), NNT 4.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chechter et al., 5 Nov 2021, prospective, Brazil, preprint, 13 authors, dosage 800mg day 1, 400mg days 2-5, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.11.05.21265569; this version posted November 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Evaluation of patients treated by telemedicine in the COVID-19 pandemic by a private clinic in São Paulo, Brazil: A non-randomized clinical trial preliminary study Michelle Chechter (MD)1*, Gustavo Maximiliano Dutra da Silva (MD, PhD)2, Thomas Gabriel Miklos (MD, PhD)3, Marta Maria Kemp (MD, PhD)4, Nilzio Antonio da Silva (MD, PhD)5, Gabriel Lober (MD)6, Marcela Ferreira Tavares Zanut (MD)7, Rute Alves Pereira e Costa8, Aline Pinheiro dos Santos Cortada9, Luciana de Nazare Lima da Cruz1, Paulo Macio Porto de Melo10, Bruno Campello de Souza11, Morton Aaron Scheinberg (MD, PhD)12** 1 CEO Centro Médico Mazzei, São Paulo, Brazil; 2 São Francisco University (USF), Bragança Paulista, Brazil; 3 Department of Obstetrics and Gynecology - Santa Casa of Sao Paulo Medical School, Sao Paulo (FCMSCSP), Brazil. 4 Kemp Institute of Integrative Health, São Paulo Brazil; 5 Federal University of Goias, Medical School, Department of Medical Clinic, Goiania, Brazil. 6 Laboratory DASA, São Paulo, Brazil; 7 Instituto CEMA, São Paulo, Brazil; 8 Sociedade Brasileira de Valorização das Sociedades Medicas—SOBEMED, São Paulo, Brazil; 9 Clinical Research Center of Associação de Assistência a Criança Deficiente, São Paulo, Brazil; 10 Departamento de Neurocirurgia, Hospital Militar de Area de São Paulo, Brazil 11 Departamento de Ciencias, Universidade Federal de Pernambuco, Recife, Brazil 12 Hospital Israelita Albert Einstein, São Paulo, Brazil. * Corresponding author: Michelle Chechter Av. Mazzei, 289 São Paulo – SP, Brasil. CEP: 02310-000 - Fone: +55 (11) 96316-2985 / (11) 2306-8120 E-mail: gumaxy@yahoo.com.br ** In memoriam NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.11.05.21265569; this version posted November 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Introduction: As a result of the coronavirus disease 2019 (COVID-19) pandemic the year 2020 brought major changes on the delivery of health care and face to face physician patient communication was significantly reduced and the practice of remote telehealth care using computer technology is assuming a standard of care, particularly, with COVID-19 patients with attempts to reduce viral spread. Objective: To describe the clinical practice experience using telemedicine towards COVID-19 and the respective clinical outcomes. Methods: We performed a pilot open-label non-randomized, controlled clinical trial. The patients were divided into four groups, according severity of symptoms: (1) asymptomatic, (2) mild symptoms, (3) moderate symptoms and (4) severe symptoms, and were followed up for five days, counted from the beginning of the symptoms. A drug intervention was performed in group 3, for which the protocol followed as suggested by the International Pulmonology Society’s consensus for adults with moderate..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit